The Pill That Ends the Injection Era
20.7% weight loss, no needles — and the 4 products GLP-1 users actually need.
ⓘ This issue contains affiliate links. If you buy through them, VITALS may earn a commission — at no extra cost to you.
The weight-loss drug that defined the last two years just lost its biggest downside — the needle. In January 2026 the FDA cleared the first oral GLP-1 for weight loss. In April, Eli Lilly’s orforglipron (Foundayo) got approved too. And the new high-dose Wegovy HD (7.2mg) hit 20.7% average weight loss at 72 weeks.
Why it matters
Scale. A pill is cheap, stable and global — the addressable population just went from millions to hundreds of millions.
Adherence. “Take a pill” beats “inject weekly” for most people. The ripple: GLP-1 trials are now reading out for heart failure, cardiovascular risk, and early Alzheimer’s signals by late 2026.
The catch nobody’s funneling you toward: GLP-1s make you eat less — which means muscle loss, electrolyte crashes and protein gaps are the #1 complaint among real users. The drug is the doctor’s job. Protecting your body is yours.
What GLP-1 users actually need
A body-composition scale
Lose fat, not muscle. Track lean mass so you know your plan is working.
Check price →Clinical-grade protein
On reduced appetite, hitting protein is the biggest lever for keeping muscle.
See top-rated →Electrolytes
Lower food intake means lower sodium and potassium — the fatigue users blame on the drug is often just this.
Shop sugar-free →VITALS reports on medicine and is not medical advice. Consult a clinician for any health decision.
